Evidence map›Paper›PMID 39528062›Full record

ArticleActa biomaterialia2026

In vitro vascularization improves in vivo functionality of human engineered cardiac tissues.

Hanjun Li, Ilya Shadrin, Abbigail Helfer, Karen Heman, Lingjun Rao, Caroline Curtis, Gregory M Palmer, Nenad Bursac

Abstract read
In one paragraph

Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026
    Review
  7. Review
  8. Review
  9. Image-Guided Cardiac Regeneration via a 3D Bioprinted Vascular Patch with Built-in CT Visibility.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanjun LiDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Ilya ShadrinDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Abbigail HelferDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Karen HemanDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Lingjun RaoDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Caroline CurtisDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Gregory M PalmerDepartment of Radiation Oncology, Cancer Biology Division at Duke University Medical Center, Duke University, NC 27708, USA.
Nenad BursacDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA. Electronic address: nbursac@duke.edu.

Funding

Integrated Cellular and Tissue Engineering for Ischemic Heart DiseaseU01HL134764 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BURSAC, NENAD, KAMP, TIMOTHY J. · 2016 to 2022
$7.7M
Exploring the role of ATP1A3 mutations in sudden unexplained death in epilepsyR01HL160654 · NHLBI · DUKE UNIVERSITY · PI Andrew P. Landstrom · 2022 to 2026
$3.4M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
Engineering Human Heart Tissues with Polyploid CardiomyocytesR01HL164013 · NHLBI · DUKE UNIVERSITY · PI BURSAC, NENAD · 2022 to 2025
$2.2M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01HL156348 · NHLBI · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2020 to 2022
$2.0M
Engineered BacNav and BacCav for Improved Excitability and ContractionR01EB032726 · NIBIB · DUKE UNIVERSITY · PI BURSAC, NENAD · 2022 to 2025
$1.9M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01EB028901 · NIBIB · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2019 to 2019
$668k
NHLBI NIH HHS R01 HL160654NHLBI NIH HHS R01 HL164013NHLBI NIH HHS U01 HL134764NHLBI NIH HHS U01 HL156348NIBIB NIH HHS R01 EB032726NIBIB NIH HHS U01 EB028901NIGMS NIH HHS T32 GM144291
6 · The paper itself

Abstract

Engineered human cardiac tissues hold great promise for disease modeling, drug development, and regenerative therapy. For regenerative applications, successful engineered tissue engraftment in vivo requires rapid vascularization and blood perfusion post-implantation. In the present study, we engineered highly functional, vascularized cardiac tissues ("cardiopatches") by co-culturing human induced pluripotent stem cell-derived cardiomyocytes (hiPSCCMs) and endothelial cells (hiPSC-ECs) in optimized serum-free media. The vascularized cardiopatches displayed stable capillary networks over 4 weeks of culture, the longest reported in the field, while maintaining high contractile stress (>15 mN/mm

Indexed as

AnastomosisCardiac patchHeart tissue engineeringhiPSC-CMhiPSC-ECVascularization

Identifiers

PMID39528062
PMCPMC12064791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.